Sarcomatrix names Jeff Myers as chief medical officer

Sarcomatrix Therapeutics has appointed Jeff Myers, M.D., Ph.D., as chief medical officer as the company pushes its lead DMD drug candidate, S-969, toward IND submission and first-in-human testing. The hire adds senior clinical and regulatory experience at a key stage for the Reno-based biotech.

Why it matters: - Sarcomatrix Therapeutics is trying to move its Duchenne muscular dystrophy program from preclinical work into the clinic. - The addition of a chief medical officer strengthens the company’s clinical development and regulatory leadership before IND submission. - S-969 targets a rare disease that affects about one in every 3,500 to 5,000 male births worldwide.

What happened: - Sarcomatrix Therapeutics appointed Jeff Myers, M.D., Ph.D., as chief medical officer. - The Reno, Nevada-based biopharmaceutical company said Myers joins as S-969 advances toward Investigational New Drug submission and first-in-human studies. - David Craig, Sarcomatrix co-founder and chief executive officer, said Myers’ background in first-in-class therapies makes him a strong addition to the leadership team.

The details: - Myers brings more than 15 years of executive leadership experience in clinical development, regulatory strategy, medical affairs and global clinical operations. - Myers previously served as chief medical officer at Beyond Air, Revolo Biotherapeutics and Portola Pharmaceuticals. - Earlier in his career, Myers practiced as a congenital cardiothoracic surgeon. - Myers also served as chief of pediatric cardiac surgery at Massachusetts General Hospital and Tulane University. - As chief medical officer, Myers will help finalize the Phase I clinical strategy for Sarcomatrix. - Myers will also support regulatory interactions and guide CRO selection. - Sarcomatrix describes S-969 as an investigational oral small-molecule therapy for Duchenne muscular dystrophy. - The company says S-969 is designed to address underlying muscle degeneration tied to the disease. - Sarcomatrix says its lead candidate is intended to improve muscle function and slow disease progression through a differentiated mechanism of action.

Between the lines: - The appointment signals Sarcomatrix is prioritizing clinical execution as it approaches a major regulatory milestone. - Myers’ mix of surgical, clinical and executive experience suggests Sarcomatrix is looking for leadership that can bridge science, operations and patient-facing development. - The company’s focus on an oral therapy may matter in a disease area where treatment burden and access remain important issues.

What's next: - Sarcomatrix plans to complete its Phase I strategy and continue regulatory work ahead of IND submission. - The company aims to move S-969 into first-in-human clinical studies. - Myers will work with Sarcomatrix leadership as the program transitions from preclinical development into the clinic. - The company has not disclosed a timeline for the IND filing or trial start.